Off label intravitreal Brolucizumab in treatment of recurrent macular edema due to branch retinal vein occlusion: A case report

A 59 year old female presented with progressive loss of vision in right eye (RE) of 6 months duration. She had been diagnosed with inferotemporal branch retinal vein occlusion with macular edema in RE and had received 4 doses of intravitreal Ranibizumab previously. Best corrected visual acuity in RE was 20/120, N24. Optical coherence tomography scans of RE showed significant cystoid macular edema with central macular thickness of 546 mu m. She was treated with single dose of intravitreal Brolucizumab (6 mg/0.05 ml). Vision improved to 20/ 32, N6 one month following injection with return to normal foveal architecture. Visual gains and reduction in central macular thickness were maintained with no recurrence of macular edema 2 months following the pro-cedure. No adverse effects were noted during the entire follow up.

Automated summary

A 59-year-old female patient presented with gradual vision loss in the right eye. After receiving Brolucizumab treatment, her vision improved and there was no recurrence of macular edema.